SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST
Status:
RECRUITING
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Phase:
PHASE2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Collaborators:
Cogent Biosciences, Inc. Dana-Farber Cancer Institute The Life Raft Group